{"corpus_id":3955365,"paper_sha":"5b5c9192229a66c9fe45a4e31634adc647651d53","doi":"10.1084/jem.20042323","arxiv_id":null,"pmid":15837811,"pmcid":"2213140","mag_id":2101553545,"dblp_id":null,"acl_id":null,"title":"Structural and kinetic basis for heightened immunogenicity of T cell vaccines","year":2005,"publication_date":"2005-04-18","venue":"Journal of Experimental Medicine","journal":{"name":"The Journal of Experimental Medicine","pages":"1243 - 1255","volume":"201"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Biology","Medicine"],"reference_count":58,"citation_count":301,"influential_citation_count":17,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Animals","mj":false,"ui":"D000818"},{"d":"Antigens, Neoplasm","mj":false,"qs":[{"q":"chemistry","mj":true,"ui":"Q000737"},{"q":"immunology","mj":false,"ui":"Q000276"}],"ui":"D000951"},{"d":"Cancer Vaccines","mj":false,"qs":[{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D019496"},{"d":"Cell Line, Tumor","mj":false,"ui":"D045744"},{"d":"Chemokine CCL4","mj":false,"ui":"D054407"},{"d":"Crystallography, X-Ray","mj":false,"ui":"D018360"},{"d":"Epitopes, T-Lymphocyte","mj":false,"qs":[{"q":"chemistry","mj":true,"ui":"Q000737"},{"q":"immunology","mj":false,"ui":"Q000276"}],"ui":"D018984"},{"d":"HLA-A2 Antigen","mj":false,"qs":[{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"immunology","mj":false,"ui":"Q000276"}],"ui":"D015789"},{"d":"Immunization","mj":false,"ui":"D007114"},{"d":"Interferon-gamma","mj":false,"qs":[{"q":"analysis","mj":false,"ui":"Q000032"}],"ui":"D007371"},{"d":"Macrophage Inflammatory Proteins","mj":false,"qs":[{"q":"analysis","mj":false,"ui":"Q000032"}],"ui":"D019402"},{"d":"Major Histocompatibility Complex","mj":false,"qs":[{"q":"immunology","mj":false,"ui":"Q000276"}],"ui":"D008285"},{"d":"Membrane Proteins","mj":false,"qs":[{"q":"chemistry","mj":true,"ui":"Q000737"},{"q":"immunology","mj":false,"ui":"Q000276"}],"ui":"D008565"},{"d":"Mice","mj":false,"ui":"D051379"},{"d":"Mice, Transgenic","mj":false,"ui":"D008822"},{"d":"Peptides","mj":false,"qs":[{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"immunology","mj":false,"ui":"Q000276"}],"ui":"D010455"},{"d":"Protein Binding","mj":false,"qs":[{"q":"immunology","mj":false,"ui":"Q000276"}],"ui":"D011485"},{"d":"Protein Conformation","mj":false,"ui":"D011487"},{"d":"Receptors, Antigen, T-Cell","mj":false,"qs":[{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"immunology","mj":true,"ui":"Q000276"}],"ui":"D011948"},{"d":"Spleen","mj":false,"qs":[{"q":"cytology","mj":false,"ui":"Q000166"},{"q":"drug effects","mj":false,"ui":"Q000187"},{"q":"immunology","mj":false,"ui":"Q000276"}],"ui":"D013154"},{"d":"T-Lymphocytes, Cytotoxic","mj":false,"qs":[{"q":"immunology","mj":true,"ui":"Q000276"}],"ui":"D013602"},{"d":"Transfection","mj":false,"ui":"D014162"},{"d":"Vaccines, Synthetic","mj":false,"qs":[{"q":"chemistry","mj":false,"ui":"Q000737"},{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D014614"}],"chemicals":[{"n":"Antigens, Neoplasm","ui":"D000951","reg":"0"},{"n":"CTAG1B protein, human","ui":"C104948","reg":"0"},{"n":"Cancer Vaccines","ui":"D019496","reg":"0"},{"n":"Chemokine CCL4","ui":"D054407","reg":"0"},{"n":"Epitopes, T-Lymphocyte","ui":"D018984","reg":"0"},{"n":"HLA-A2 Antigen","ui":"D015789","reg":"0"},{"n":"Macrophage Inflammatory Proteins","ui":"D019402","reg":"0"},{"n":"Membrane Proteins","ui":"D008565","reg":"0"},{"n":"Peptides","ui":"D010455","reg":"0"},{"n":"Receptors, Antigen, T-Cell","ui":"D011948","reg":"0"},{"n":"Vaccines, Synthetic","ui":"D014614","reg":"0"},{"n":"Interferon-gamma","ui":"D007371","reg":"82115-62-6"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://rupress.org/jem/article-pdf/201/8/1243/1153223/jem20181243.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/5b5c9192229a66c9fe45a4e31634adc647651d53","s2_open_access_license":"CCBYNCSA","s2_open_access_status":"BRONZE","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Analogue peptides with enhanced binding affinity to major histocompatibility class (MHC) I molecules are currently being used in cancer patients to elicit stronger T cell responses. However, it remains unclear as to how alterations of anchor residues may affect T cell receptor (TCR) recognition. We correlate functional, thermodynamic, and structural parameters of TCR–peptide–MHC binding and demonstrate the effect of anchor residue modifications of the human histocompatibility leukocyte antigens (HLA)–A2 tumor epitope NY–ESO-1157–165–SLLMWITQC on TCR recognition. The crystal structure of the wild-type peptide complexed with a specific TCR shows that TCR binding centers on two prominent, sequential, peptide sidechains, methionine–tryptophan. Cysteine-to-valine substitution at peptide position 9, while optimizing peptide binding to the MHC, repositions the peptide main chain and generates subtly enhanced interactions between the analogue peptide and the TCR. Binding analyses confirm tighter binding of the analogue peptide to HLA–A2 and improved soluble TCR binding. Recognition of analogue peptide stimulates faster polarization of lytic granules to the immunological synapse, reduces dependence on CD8 binding, and induces greater numbers of cross-reactive cytotoxic T lymphocyte to SLLMWITQC. These results provide important insights into heightened immunogenicity of analogue peptides and highlight the importance of incorporating structural data into the process of rational optimization of superagonist peptides for clinical trials.","claims":[{"public_id":"cl_93902e6c1a9516e389ca4eb3e8b34842","status":"active","text":"Anchor residue modification of the HLA-A2 tumor epitope NY-ESO-1157-165-SLLMWITQC alters T cell receptor recognition by subtly enhancing peptide-TCR interactions.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_93902e6c1a9516e389ca4eb3e8b34842"},{"public_id":"cl_015dc08829e7012ef0df91b1abbe9f9b","status":"active","text":"Cysteine-to-valine substitution at peptide position 9 tightens binding to HLA-A2, improves soluble TCR binding, and repositions the peptide main chain.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_015dc08829e7012ef0df91b1abbe9f9b"},{"public_id":"cl_378d9600b1031ccdd209fdfce7ae8995","status":"active","text":"Recognition of the analogue peptide accelerates lytic granule polarization, reduces dependence on CD8 binding, and increases the number of cross-reactive cytotoxic T lymphocytes.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_378d9600b1031ccdd209fdfce7ae8995"},{"public_id":"cl_a52e2381a36c79f31dec5348c3477388","status":"active","text":"Structural data are important for rational optimization of superagonist peptides for clinical trials.","confidence":0.88,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a52e2381a36c79f31dec5348c3477388"},{"public_id":"cl_b1d19dab06c5a1a3665887aa8a4007dc","status":"active","text":"The wild-type peptide bound to the specific TCR is recognized through two prominent sequential peptide side chains, methionine and tryptophan.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_b1d19dab06c5a1a3665887aa8a4007dc"}],"concepts":[{"public_id":"co_1ff5684e7e195c1afa702cb7ef4a00d8","status":"active","name":"cross-reactive cytotoxic T lymphocytes","description":"Cytotoxic T lymphocytes that recognize both the analogue peptide and the original peptide sequence.","types":["immune cell"],"aliases":["cross-reactive CTL"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1ff5684e7e195c1afa702cb7ef4a00d8"},{"public_id":"co_2217265f778552e838352dae92761cd9","status":"active","name":"wild-type peptide","description":"The original peptide sequence used as the reference in the structural comparison.","types":["peptide"],"aliases":["wild-type peptide complex"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2217265f778552e838352dae92761cd9"},{"public_id":"co_2640a28115a727e448835881ca5cfede","status":"active","name":"anchor residue modifications","description":"Changes to peptide residues that primarily affect binding to the MHC molecule.","types":["modification"],"aliases":["alterations of anchor residues"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2640a28115a727e448835881ca5cfede"},{"public_id":"co_27eccf8d62515394bbdde21012bac204","status":"active","name":"T cell receptor recognition","description":"The process by which a T cell receptor binds and responds to a peptide-MHC complex.","types":["immune recognition"],"aliases":["TCR recognition"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_27eccf8d62515394bbdde21012bac204"},{"public_id":"co_2eb134f19ebedf94bcd6652f912c44af","status":"active","name":"soluble TCR binding","description":"Binding of a purified, soluble T cell receptor to a peptide-MHC complex.","types":["binding measurement"],"aliases":["soluble T cell receptor binding"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2eb134f19ebedf94bcd6652f912c44af"},{"public_id":"co_34d89d330bca60564086b79b014d35cc","status":"active","name":"HLA-A2 tumor epitope NY-ESO-1157-165-SLLMWITQC","description":"A human HLA-A2-restricted tumor epitope derived from NY-ESO-1 spanning residues 157 to 165.","types":["epitope"],"aliases":["NY-ESO-1157-165-SLLMWITQC","NY-ESO-1 157-165"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_34d89d330bca60564086b79b014d35cc"},{"public_id":"co_3d918823fc618e99d4d390fba3dcca77","status":"active","name":"HLA-A2","description":"A human major histocompatibility class I molecule that presents peptide antigens.","types":["MHC class I molecule"],"aliases":["human histocompatibility leukocyte antigen A2"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3d918823fc618e99d4d390fba3dcca77"},{"public_id":"co_416738d80589f64429eec31edf845adc","status":"active","name":"specific TCR","description":"The particular T cell receptor used in the structural and binding analyses.","types":["receptor"],"aliases":["specific T cell receptor"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_416738d80589f64429eec31edf845adc"},{"public_id":"co_586919be3fd68ef6b9159c7e47d8f7ea","status":"active","name":"superagonist peptides","description":"Peptide ligands engineered to stimulate unusually strong T cell responses.","types":["peptide"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_586919be3fd68ef6b9159c7e47d8f7ea"},{"public_id":"co_72c47d94dc3ce80542bc6d048feb79b8","status":"active","name":"lytic granule polarization","description":"Movement of cytotoxic granules toward the immunological synapse during T cell activation.","types":["cellular process"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_72c47d94dc3ce80542bc6d048feb79b8"},{"public_id":"co_794a655a64b2f6fb4f6d37673b2e991d","status":"active","name":"analogue peptide","description":"A modified peptide variant designed to bind more strongly to MHC and alter T cell recognition.","types":["peptide variant"],"aliases":["analogue peptides"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_794a655a64b2f6fb4f6d37673b2e991d"},{"public_id":"co_91e092679cc709da0746efc8bfa88020","status":"active","name":"peptide side chains","description":"Side-chain groups of peptide residues that contact the T cell receptor in the crystal structure.","types":["molecular feature"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_91e092679cc709da0746efc8bfa88020"},{"public_id":"co_b7902011e055338e79923f7b93db7762","status":"active","name":"cysteine-to-valine substitution","description":"An amino acid substitution at peptide position 9 that changes cysteine to valine.","types":["mutation"],"aliases":["C-to-V substitution"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b7902011e055338e79923f7b93db7762"},{"public_id":"co_cfe23f9a55172acb455fa53b18317275","status":"active","name":"structural data","description":"Three-dimensional structural information used to interpret molecular interactions and guide peptide optimization.","types":["evidence"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_cfe23f9a55172acb455fa53b18317275"},{"public_id":"co_fc956f75d3c4330c0953a98b75386714","status":"active","name":"clinical trials","description":"Human studies used to evaluate candidate therapeutic interventions.","types":["study type"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fc956f75d3c4330c0953a98b75386714"}],"external_ids":{"DOI":"10.1084/jem.20042323","ArXiv":null,"PubMed":15837811,"PubMedCentral":"2213140","MAG":2101553545,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://rupress.org/jem/article-pdf/201/8/1243/1153223/jem20181243.pdf","landing_url":"https://www.semanticscholar.org/paper/5b5c9192229a66c9fe45a4e31634adc647651d53","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCSA","status":"BRONZE","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631023,"paper_uid":"42ca8657-7712-4315-aa1b-c656f57a39b5","canonical_identity":{"paper_id":631023,"paper_uid":"42ca8657-7712-4315-aa1b-c656f57a39b5","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/3955365"}